Business
BullFrog AI Unveils bfARENAS™ Scenario-based Decision Engine
Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial
About this update from Bullfrog Ai Holdings, Inc.
[{"type":"text","content":"Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D portfolios\nGAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (\"BullFrog AI\" or the \"Company\"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, today unveiled bfARENAS™, a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design, bolstering its end-to-end AI intelligence workflow. The Company will host a webinar in partnership with Xtalks Life Sciences on bfARENAS™ on March 27, 2026 at 11 a.m. ET. Organizations across biotech, pharma, and clinical research operate in high-uncertainty environments where timelines are long, capital is constrained, and roughly 90% of clinical trials ultimately fail,” said BullFrog AI Founder and CEO Vin Singh. “Despite the explosion of data, many teams still lack a structured, transparent way to translate evidence into consistent R&D decisions, leading to inefficient capital deployment. With bfARENAS™, we take a different approach - we treat strategic scenarios as first-class inputs and use structured comparison to surface recommendations that hold up across multiple futures. The result is clearer R&D strategy and diversified, risk-balanced portfolios that can accelerate the development of innovative therapeutics.” About bfARENAS™ bfARENAS™ completes the Company's end-to-end intelligence workflow by adding a strategic decision layer to complement existing products bfPREP™ and bfLEAP®. Unlike traditional portfolio machine learning tools that collapse complex judgments into single scores and fixed weightings, bfARENAS™ evaluates options through head-to-head comparison across multiple strategic scenarios, revealing which programs are robust winners and which succeed only under narrow conditions. Combining multiple algorithmic approaches, bfARENAS™ is able to provide biotech and pharmaceutical companies with trackable and explainable decisions for targeted selections to accelerate drug discovery and development programs. Key capabilities of bfARENAS™ include: Comparing drug programs, drug targets, biomarkers, indications...